Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03979638 · ClinicalTrials.gov registry record · Phase 2
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
A Phase 2 study, sponsored by Bellus Health Inc. - a GSK company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT03979638: Clinical Trial Phase 2 study, sponsored by Bellus Health Inc. - a GSK company.
NCT03979638 is a Phase 2 study that was terminated before completion, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 68 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03979638, a Phase 2 study, was terminated before completion, sponsored by Bellus Health Inc. - a GSK company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
Primary Outcome
Change in awake cough frequency (average hourly cough frequency while the subject is awake ) evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected
Interventions
- DRUG Placebo
- DRUG BLU-5937
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2019-07-10 |
| Est. Completion | 2020-04-23 |
| Phase | Phase 2 |
Why NCT03979638 stopped before completion
NCT03979638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03979638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03979638 about?
NCT03979638 is a clinical study titled "A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough". This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
What is the current status of trial NCT03979638?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2019-07-10. Estimated completion is 2020-04-23.
What interventions are being tested in trial NCT03979638?
The interventions under investigation include: Placebo (DRUG), BLU-5937 (DRUG).
Who is sponsoring clinical trial NCT03979638?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03979638's enrollment target sits among peer trials
68 967th of 2000 higher than 1,027 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI